Macular Disease Foundation Australia logo

    MDFA position statement re 2RT laser.

    Media release: 24 September 2018.

    MDFA position statement re 2RT laser

    The LEAD study or Laser Intervention in Early Stages of Age-Related Macular Degeneration is a world-first study into the safety and efficacy of the 2RT laser as a possible treatment for people with the earlier stages of AMD (drusen), to slow or prevent progression to late stage AMD.

    The laser has been developed by Ellex Medical Lasers Limited, an Australian manufacturer of medical devices based in Adelaide.

    The three-year study was coordinated by the Centre for Eye Research Australia (CERA) in Melbourne, and carried out across a number of sites in Australia and Northern Ireland. The Principal Investigator for the LEAD study was Professor Robyn Guymer from CERA.

    While not a cure, the results from this important study are interesting and promising.

    MDFA, through advice from its Medical Committee, believes that further research is needed before 2RT laser can be considered a standard treatment.

    At this stage, until further studies into the long-term efficacy and safety are available, the Foundation only recommends the use of this laser within a well conducted clinical trial setting.

    There is ongoing research into the treatment of the early stages of AMD, and there is a great need for effective treatment to slow or prevent progression to late AMD, the vision-threatening stage of the disease.

    Anyone wishing to participate in clinical trials can indicate their interest by contacting MDFA on 1800 111 709, or by registering through the CERA website.

    Posted: 24 September 2018

    More articles like this